President of Selecta Biosciences Inc., becomes a member of the Scientific-Expert Council of the first Innovative Biopharmaceutical Cluster in Russia
Werner Cautreels, Ph.D., President and CEO of Selecta Biosciences, Inc., (Massachusetts, USA), a well-known expert with extensive experience in managing big pharma and biotech, becomes a member of the Scientific-Expert Council of Biopharmaceutical Cluster “Northern” based at MIPT.
Scientific-Expert Council of BPC “Northern”—is an advisory and expert body responsible for analyzing the major trends in the pharmaceutical market, and in key innovations and R&D developments. The Council also reviews new applications and projects submitted to the BPC “Northern” that are seeking financing, as well as current projects of various kinds.
The Scientific-Expert Council is composed of renowned world-class specialists who have international competence in relevant areas of science and business. Council members posses in-depth knowledge, extensive expertise and strong connections within the market, thus can evaluate different kinds of projects as well as recommend the best cooperation models for Russian and foreign partners.
Prior to joining Selecta Biosciences, Dr. Werner Cautreels was CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories in February 2010. Previously Dr. Werner Cautreels headed R&D Departments at Sanofi, Sterling-Winthrop, and Nycomed-Amersham, located in Europe and US. Today, Dr. Werner Cautreels manages Selecta Biosciences, Inc., and is a Board member of Galapagos NV (Mechelen, Belgium). Until June 2010 he was also the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus. Dr. Werner Cautreels graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
“It is an honor to be part of the Scientific Advisory Board of the Northern Biopharm Cluster” said Dr. Werner Cautreels, PhD, President and CEO of Selecta Biosciences. “The partners of the Cluster offer a wealth of basic science, know-how, and experience in all aspects of the biopharmaceutical field and should be able to attract further world-class investments and companies. It will be a privilege to contribute to further success of the Cluster”.
Chairman of the Supervisory Board of BPC “Northern”, the Rector of MIPT, Mr. Kudryavtsev, said: “We welcome such a great expert as Dr. Werner Cautreels. His expertise in applied industrial science will be extremely useful and beneficial for our development — we hope that the involvement of Dr. Werner Cautreels in our pharm cluster will strengthen cooperation between MIPT, domestic and western industry, as well as scientific society”.
BPC “Northern” will continue to work on the expansion of its Scientific-Expert Council.
Selecta Biosciences, Inc.—is developing a new class of vaccines on the platform tSVP™, providing antigen-specific activation of the immune system, or antigen-specific immune tolerance for therapeutic and prophylactic use. The technological platform of synthetic vaccines SVP™, proprietary to Selecta Biosciences, provides a new paradigm in vaccine development, allowing a robust immune response to a wide range of antigens, while limiting side effects. Research programs include the development of prophylactic and therapeutic vaccines widely used, including infectious diseases and cancer, diabetes , and smoking cessation.
In 2011, RUSNANO together . with Selecta Biosciences, Inc. founded Selecta RUS LLC.
BPC “Northern”—MIPT association with small innovative companies, research organizations, industrial companies, assisted by the Ministry of Industry and Trade of the Russian Federation, Moscow Region Government, City administrations and Dolgoprudnyy Khimki. BPC «Northern» strives to create around MIPT a belt of small innovative companies and corporate laboratories.
Among the members of BPC «Northern» apart from MIPT are fund «Skolkovo», Center for High Technology «ChemRar», Akrikhin, PROTEK Group, FSUE RPC Pharmzaschita and etc.